Results 61 to 70 of about 32,676 (224)

Tranexamic Acid in Lower Extremity Endoprosthetic Reconstruction for Oncologic Indications: A Retrospective Comparative Study of 617 Patients

Journal of Surgical Oncology, EarlyView.
ABSTRACT Background and Objectives While tranexamic acid (TXA) reduces blood loss in orthopedic surgery, thromboembolic concerns in cancer patients have limited adoption in orthopedic oncology. This study evaluated TXA efficacy and safety in patients undergoing endoprosthetic reconstruction for oncologic indications.
Stephen W. Chenard, Akhil Rekulapelli, Riley S. Gilbertson, Connor S. Charton, William F. Hefley, Michael J. Colello, Jennifer L. Halpern, Herbert S. Schwartz, Daniel J. Johnson, Jonathan G. Schoenecker, Joshua M. Lawrenz   +10 more
wiley   +1 more source

Impact of rivaroxaban on point-of-care assays

, 2017
BACKGROUND: Point-of-care testing (POCT) is regularly used to assess haemostasis in various clinical settings. The impact of rivaroxaban on those POCT is still elusive.
Hans Stricker, Mendez, Adriana, Schmid, Pirmin, Wolfgang Korte, Walter A. Wuillemin, Adriana Mendez, Michael Nagler, Studt, Jan-Dirk, Stricker, Hans, Alberio, Lorenzo, Pirmin Schmid, Dimitrios A. Tsakiris, Angelillo-Scherrer, Anne, Lorenzo Alberio, Tsakiris, Dimitrios A, Anne Angelillo-Scherrer, Lars M. Asmis, Pierre Fontana, Jan-Dirk Studt, Asmis, Lars, Asmis, Lars M, Nagler, Michael, Fontana, Pierre, Korte, Wolfgang, Wuillemin, Walter A   +24 more
core   +1 more source

Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial

, 2020
Aims: To investigate the efficacy and safety of early transition from hospital to ambulatory treatment in low-risk acute PE, using the oral factor Xa inhibitor rivaroxaban.
Barco, S., Bauersachs, R. M., Lankeit, M., Otero Candelera, Remedios, Schmidtmann, I., Bernardi, E., Ageno, W., Becattini, C.   +7 more
core   +1 more source

Development of a physiologically‐based pharmacokinetic model for Ritonavir characterizing exposure and drug interaction potential at both acute and steady‐state conditions

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 523-539, March 2025.
Abstract Ritonavir (RTV) is a potent CYP3A inhibitor that is widely used as a pharmacokinetic (PK) enhancer to increase exposure to select protease inhibitors. However, as a strong and complex perpetrator of CYP3A interactions, RTV can also enhance the exposure of other co‐administered CYP3A substrates, potentially causing toxicity.
Lien Thi Ngo, Woojin Jung, Tham Thi Bui, Hwi‐yeol Yun, Jung‐woo Chae, Jeremiah D. Momper   +5 more
wiley   +1 more source

Rapid Determination of Rivaroxaban by Using Terahertz Metamaterial Biosensor

Photonics
Rivaroxaban, a direct oral anticoagulant, is widely used in the management and prevention of thrombotic conditions. Dose adjustments are necessary to optimize efficacy based on individual physiological differences. However, current analytical methods are
Xinghao Huang, Jing Wu, Xu Wu, Yan Peng
doaj   +1 more source

Symptomatic hepatocellular liver injury with hyperbilirubinemia in two patients treated with rivaroxaban

, 2014
Treatment with the new oral anticoagulant rivaroxaban can be associated with severe liver injury.; We report 2 patients with predominantly hepatocellular liver injury that had onset during treatment with rivaroxaban.
Heim, Markus, Terracciano, Luigi, Rätz Bravo, Alexandra E., Krähenbühl, Stephan, Liakoni, Evangelia, Rätz Bravo, Alexandra E   +5 more
core   +1 more source

Rivaroxaban plasma levels in acute ischemic stroke and intracerebral hemorrhage

, 2018
Information about Rivaroxaban plasma levels (RivLev) may guide treatment decisions in patients with acute ischemic stroke (AIS) and intracerebral hemorrhage (ICH) taking ...
Thilemann, Sebastian, Kägi, Georg, Sandor, Peter S, Engelter, Stefan T, Cappellari, Manuel, Emmanuel De Maistre, De Marchis, Gian Marco, Manuel Cappellari, Susanne Wegener, Berge, Eivind, Sebastian Thilemann, De Maistre, Emmanuel, Nils Peters, Béjot, Yannick, Schädelin, Sabine, Stefan T. Engelter, Eivind Berge, Gian Marco De Marchis, Zini, Andrea, Monika Kapauer, Zedde, Marialuisa, David Werring, Alexandros A. Polymeris, null null, Guillaume Turc, Andrea Zini, Andreas Luft, Marcel Arnold, Kapauer, Monika, Patrik Michel, Seiffge, David J, Traenka, Christopher, Arnold, Marcel, Turc, Guillaume, Marialuisa Zedde, Fischer, Urs, Dimtrios A. Tsakiris, Sabine Schädelin, Cordonnier, Charlotte, Werring, David, Urs Fischer, Jochen Vehoff, Luft, Andreas, David J. Seiffge, Michel, Patrik, Ilaria Maestrini, Charlotte Cordonnier, Sirimarco, Gaia, Tsakiris, Dimitrios A, Bonati, Leo H, Leo H. Bonati, Vehoff, Jochen, Maestrini, Ilaria, Georg Kägi, Peters, Nils, Yannick Béjot, Gaia Sirimarco, Philippe A. Lyrer, Tsakiris, Dimtrios A, Lyrer, Philippe A, Polymeris, Alexandros A, Gilles Rodier, Rodier, Gilles, Christopher Traenka, Wegener, Susanne, Peter S. Sandor   +65 more
core   +1 more source

Rivaroxaban and Hemostasis in Emergency Care [PDF]

, 2020
Rivaroxaban is an oral, direct Factor Xa inhibitor, approved for the prevention and treatment of several thromboembolic disorders. Rivaroxaban does not require routine coagulation monitoring and has a short half-life. However, confirmation of rivaroxaban
Edita Rutkauskaite, Jürgen Koscielny
core  

Platelet function in patients undergoing major non‐cardiac vascular surgery (PLUGS): a prospective cohort study*

Anaesthesia, EarlyView.
Summary Introduction Patients who require major vascular surgery often receive antiplatelet therapy for primary or secondary prevention of cardiovascular disease. Clopidogrel resistance and variability in platelet recovery after drug discontinuation pose clinical challenges, particularly for regional anaesthesia and blood management.
Akshay Shah, Grace Polley, Kasia Bera, Keith Maher, Stephen Von‐Kier, Antonio Barbosa, Louis Corrigan, Sabeena Sharma, Peter Baker, Stuart R. McKechnie, Michael J. Desborough, on behalf of the PLUGS Investigators   +11 more
wiley   +1 more source

Rivaroxaban in atrial fibrillation

, 2012
Mariano A Giorgi,1,2 Lucas San Miguel31Cardiology Service, Centro de Educación Médica e Investigaciones Clínicas “Norberto Quirno”, 2Department of Pharmacology, School of Medicine, Universidad Austral,
Giorgi MA, Miguel LS
core